Home > For Patients > Contact Us Privacy Statement Terms of Use Search Go
Kineret® (anakinra) A biologic alternative
Kineret® Prescribing Information E-Mail to a Colleague Printer Friendly Page
Patient Assistance Program
Professional Info:
 

The SAFETY NET® Foundation provides access to Kineret® for patients who meet the financial eligibility requirements.

To learn more about the SAFETY NET® Foundation for Kineret® or to request an application form, please call
1-866-KINERET (1-866-546-3738). To download a PDF copy of the SAFETY NET® instructions and application form, please click on the link below.

Download SAFETY NET® Instructions and Application (PDF, 32 Kb)

 
You need to have Adobe® Acrobat® installed to view PDF files. If you do not have Acrobat® Reader®, you can download it for free from the Adobe® website. Get Adobe Acobat Reader
 
Adobe® Reader® is a registered trademark of Adobe Systems, Inc.
 
ABOUT KINERET®
ABOUT IL-1
PROFESSIONAL RESOURCES
REIMBURSEMENT
IMPORTANT PRODUCT SAFETY INFORMATION
GLOSSARY
 

Kineret® (anakinra) is indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease-modifying antirheumatic drugs (DMARDs). Kineret® can be used alone or in combination with DMARDs other than tumor necrosis factor (TNF) blocking agents.

In clinical trials, there was a risk of serious infections (2% in Kineret® patients vs. less than 1% in placebo patients). Kineret® should be discontinued if a patient develops an infection, however most patients can continue taking Kineret® after their infection resolves. Kineret® should not be used with TNF-blocking agents such as etanercept, adalimumab, and infliximab. A 7% rate of serious infections was observed in a 24-week study of concurrent administration of Kineret® and etanercept. Kineret® is contraindicated in patients with known hypersensitivity to E coli-derived proteins, Kineret®, or any components of the product. The most common side effect in clinical trials was injection site reaction, which was usually mild and characterized by redness, swelling, and pain.
Amgen.com | Site Map
© 2008 Amgen. All rights reserved. This site is intended for U.S. health care professionals only.
Amgen®